Hengrui Medicine (600276.SH) reported a 29.67% increase in net profit attributable to shareholders to 4.45 billion yuan in the first half of the year, with rapid growth in sales revenue of innovative drugs.

Zhitong Finance APP News, Hengrui Medicine (600276.SH) released its semi-annual report for 2025, with the company's operating income reaching 15.761 billion yuan, a year-on-year increase of 15.88%. The net profit attributable to shareholders of the listed company was 4.45 billion yuan, a year-on-year increase of 29.67%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 4.273 billion yuan, a year-on-year increase of 22.43%. The basic earnings per share were 0.7 yuan.